Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.

Telomir-1 elongates telomere caps on human normal embryonic fibroblast cells by stimulating the enzyme telomerase that protects the DNA and genetic material in chromosomes to combat aging

Demonstrated a 40% increase in telomerase activity and lengthened telomeres in vitro in human cells

Provided pre-clinical endpoints to determine “anti-aging” and “age-reversal” effects in dogs

Outlined timeline for initiating human investigational new drug (IND) trials for osteoarthritis, along with animal IND (AIND) trials

WASHINGTON, April 16, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on Telomir-1 as a potential treatment for age-related conditions, today recapped its presentation of compelling pre-clinical data on Telomir-1 at a high-profile event hosted at the National Press Club in Washington, D.C., on April 15, 2024.

Dr. Chris Chapman, Co-founder, Chairman, CEO, President and Chief Medical Officer of Telomir, and Dr. Michael Roizen, special advisor to Telomir on age reversal, spearheaded the presentation, showcasing the remarkable prospects for Telomir- 1 to potentially allow the body to repair itself and mitigate effects typically associated with aging.

As part of its commitment to transparency and openness in sharing its research data, during the event, Drs. Chapman and Roizen presented company data that showed the effect of Telomir-1, a novel molecule designed to modulate telomerase activity and elongate telomeres. The data show that telomeres lengthened in vitro in human cells and telomerase activity increased by 40%.  

The presentation also described demonstrable pre-clinical animal testing endpoints for determining Telomir-1’s potential for “age reversal” or “anti-aging” effects such as gait strength or weakness, joint damage assessment, dynamic weight bearing, clinical chemistry, hematology, telomere length and change in synovial fluids.

Dr. Chapman also outlined the anticipated timeline for initiating human clinical trials for osteoarthritis, along with veterinary clinical trials, both of which are targeted for the second and third quarter of 2025 following anticipated pre-clinical, IND enabling studies in animals during 2024.

“Our National Press Club event was our first opportunity to share on a national stage Telomir-1’s potential to combat the diseases of aging,” stated Dr. Chapman. “We believe that the pre-clinical data were encouraging and demonstrated Telomir-1’s potential to treat age-related conditions. We remain committed to keeping the public updated as we move through the pre-clinical, IND and AIND processes and beyond.”